S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
NASDAQ:GLMD

Galmed Pharmaceuticals - GLMD Stock Forecast, Price & News

$0.71
-0.03 (-4.05%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.71
▼
$0.77
50-Day Range
$0.29
▼
$0.90
52-Week Range
$0.29
▼
$1.84
Volume
161,489 shs
Average Volume
125,795 shs
Market Capitalization
$17.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Galmed Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
604.2% Upside
$5.00 Price Target
Short Interest
Healthy
0.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Galmed Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.73) to ($0.64) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

687th out of 1,029 stocks

Pharmaceutical Preparations Industry

347th out of 501 stocks

See Top Rated MarketRank™ Stocks Here
GLMD stock logo

About Galmed Pharmaceuticals (NASDAQ:GLMD) Stock

Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Receive GLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

GLMD Stock News Headlines

February 2, 2023 | americanbankingnews.com
Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.com
February 2, 2023 | americanbankingnews.com
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Receives Average Recommendation of "Hold" from Analysts
February 4, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
January 25, 2023 | americanbankingnews.com
Galmed Pharmaceuticals (NASDAQ:GLMD) Receives New Coverage from Analysts at StockNews.com
January 6, 2023 | finance.yahoo.com
Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?
January 4, 2023 | marketwatch.com
Galmed Pharmaceuticals Shares Up 9.2% on Data From Liver Treatment Aramchol Study
January 4, 2023 | finance.yahoo.com
Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol
December 14, 2022 | finance.yahoo.com
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement
February 4, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
September 14, 2022 | finance.yahoo.com
Galmed Pharmaceuticals (GLMD) Moves to Buy: Rationale Behind the Upgrade
August 4, 2022 | finance.yahoo.com
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
July 7, 2022 | finance.yahoo.com
Galmed's Aramchol Shows Anti-Fibrotic Effects In Lung Fibrosis Animal Model
July 7, 2022 | nasdaq.com
Galmed: New Data Reinforces Expansion Of Aramchol's Clinical Development To Additional Indications
July 7, 2022 | finance.yahoo.com
Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model
June 17, 2022 | finance.yahoo.com
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
May 25, 2022 | benzinga.com
Galmed Pharmaceuticals (NASDAQ:GLMD), Analyst Ratings, Price Targets, Predictions
May 18, 2022 | seekingalpha.com
Galmed Pharmaceuticals shares fall after downgrade by Raymond James analyst
May 17, 2022 | finance.yahoo.com
Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects
May 17, 2022 | finance.yahoo.com
Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results
May 3, 2022 | marketwatch.com
Galmed Pharmaceuticals Shares Down 16%
May 3, 2022 | markets.businessinsider.com
Raymond James Maintains Outperform Rating for Galmed Pharmaceuticals: Here's What You Need To Know
May 2, 2022 | seekingalpha.com
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2021 Results - Earnings Call Transcript
May 2, 2022 | finance.yahoo.com
Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results
April 29, 2022 | benzinga.com
Galmed Pharmaceuticals's Earnings Outlook
April 28, 2022 | finance.yahoo.com
Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment
April 26, 2022 | finance.yahoo.com
Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2
January 11, 2022 | seekingalpha.com
Galmed gains 5% after securing three new U.S. patents for Aramchol and meglumine salt
See More Headlines
Receive GLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

GLMD Company Calendar

Last Earnings
11/16/2022
Today
2/04/2023
Next Earnings (Estimated)
5/01/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GLMD
CUSIP
N/A
CIK
1595353
Web
www.galmedpharma.com
Phone
(723) 693-8448
Fax
972-3693-8447
Employees
18
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+604.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.90)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-32,470,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-97.97%
Return on Assets
-80.42%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
4.07
Quick Ratio
4.07

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.22 per share
Price / Book
0.58

Miscellaneous

Outstanding Shares
25,090,000
Free Float
20,121,000
Market Cap
$17.81 million
Optionable
Optionable
Beta
1.18

Key Executives

  • Allen Baharaff
    Chairman, President & Chief Executive Officer
  • Guy Nehemya
    Chief Operating & Data Protection Officer
  • Doron Cohen
    Chief Financial Officer
  • Liat Hayardeny
    Chief Scientific Officer
  • Neta Tobis
    Director-Clinical Affairs

Key Competitors

View All Competitors













GLMD Stock - Frequently Asked Questions

Should I buy or sell Galmed Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GLMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLMD, but not buy additional shares or sell existing shares.
View GLMD analyst ratings or view top-rated stocks.

What is Galmed Pharmaceuticals' stock price forecast for 2023?

5 brokerages have issued twelve-month target prices for Galmed Pharmaceuticals' stock. Their GLMD share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 604.2% from the stock's current price.
View analysts price targets for GLMD or view top-rated stocks among Wall Street analysts.

How have GLMD shares performed in 2023?

Galmed Pharmaceuticals' stock was trading at $0.50 at the beginning of 2023. Since then, GLMD stock has increased by 42.0% and is now trading at $0.71.
View the best growth stocks for 2023 here.

When is Galmed Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 1st 2023.
View our GLMD earnings forecast.

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) posted its earnings results on Wednesday, November, 16th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.06.

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP).

What is Galmed Pharmaceuticals' stock symbol?

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

Who are Galmed Pharmaceuticals' major shareholders?

Galmed Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galmed Pharmaceuticals' stock price today?

One share of GLMD stock can currently be purchased for approximately $0.71.

How much money does Galmed Pharmaceuticals make?

Galmed Pharmaceuticals (NASDAQ:GLMD) has a market capitalization of $17.81 million. The biopharmaceutical company earns $-32,470,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis.

How can I contact Galmed Pharmaceuticals?

Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The official website for the company is www.galmedpharma.com. The biopharmaceutical company can be reached via phone at (723) 693-8448, via email at investor.relations@galmedpharma.com, or via fax at 972-3693-8447.

This page (NASDAQ:GLMD) was last updated on 2/4/2023 by MarketBeat.com Staff